ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IMVT / news
KOD (54) CGON (42) SRRK (41) CRSP (35) ⌘ Pro Terminal →

Why IMVT Stock surged +2.22% Today — RQD Quant Desk Flash

$29.04 +2.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.10

Immunovant Inc. (IMVT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.87B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMVT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Immunovant Inc. (NASDAQ: IMVT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.04 (+2.22% 1D, market cap $5.87B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IMVT ranks #526 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMVT compare to KOD and CGON in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMVT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KOD (Kodiak Sciences Inc) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $6.14B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, IMVT leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMVT?
▼

Per IMVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001764013), Immunovant Inc. generated $1.67B in revenue (+22.2% YoY), -$505.6M in net income, and -$407.3M in free cash flow against $1.05B in total assets and $29.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $29.10 (+0.21%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (5)SEC (14)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$48 Bull$26 Base$21 Bear
📬 FREE IMVT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMVT)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY IMVT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (38% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$27.51+5.8% Next Q
Q2 (-2Q)
32
Grade E$29.10+1.9% Next Q
Q3 (-1Q)
34
Grade E$29.64-2% Next Q
Current
37
Grade D-$29.04-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMVT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMVT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.39) and Max Pain ($30.49) forces dealer call-delta covering toward $47.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMVT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMVT Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IMVT Stock surged +2.22% Today — RQD Quant Desk Flash

Immunovant Inc. (IMVT) surged +2.22% to $29.04, trading at 32% of its 52-week range ($21.43 – $45.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 32% of its 52-week range ($21.43 – $45.42) with RSI-14 at 36.4 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $29.04 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live IMVT Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMVT)

  • ✓Walkthrough of IMVT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IMVT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.31%📐 HORIZONTAL RANGE
2026-11-04O $29.17H $29.17L $28.41C $29.04VOL 1.27M
RES: $53.53SUP: $23.95SMA50: $33.39SMA200: $32.10
$47.04$40.34$33.63$26.93$20.23RES $53.53SUP $23.95$29.042026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMVT Butterfly Map → + Track IMVT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
27.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMVT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMVT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMVT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMVT)

Health Care Rank #526 of 1015 ⚔️ KOD vs IMVT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMVT vs. KOD, CGON, SRRK, CRSP)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Immunovant Inc. (IMVT) ranks #526 by composite RQD confidence (37/100, grade D-) and #145 by equity capitalization ($5.87B). Within this direct 5-issuer industry benchmark cohort, IMVT leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with IMVT at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IMVT ACTIVE
Immunovant Inc.
D- 37/100 — — -35.0% +2.22% $5.87B Benchmark Subject
KOD
Kodiak Sciences Inc
D+ 54/100 — — -35.0% +1.30% $6.14B /kod-vs-imvt →
CGON
CG Oncology Inc.
D- 42/100 — — -20.8% +3.39% $5.49B /cgon-vs-imvt →
SRRK
Scholar Rock Holding Corporation
D- 41/100 — — -35.0% +2.49% $5.23B /srrk-vs-imvt →
CRSP
CRISPR Therapeutics AG
D- 35/100 — — -30.6% 0.00% $4.83B /crsp-vs-imvt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001764013 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Immunovant Inc. (IMVT) reported GAAP revenue of $1.67B (+22.2% vs. FY2024 revenue of $1.37B , and +95.0% cumulative change since FY2023) , GAAP net income of -$505.6M, operating cash flow of -$407.3M, and free cash flow of -$407.3M (-8.1% YoY). On the balance sheet, IMVT closed FY2025 with $1.05B in total assets against $29.8M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $1.67B -$505.6M -$407.3M -$407.3M $1.05B $29.8M
FY2024 (FY) 2025-03-31 $1.37B -$413.8M -$375.9M -$376.6M $420.9M $30.7M
FY2023 (FY) 2024-03-31 $856.8M -$259.3M -$214.2M -$214.2M $3.37B $787.9M

3. IMVT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Immunovant Inc. (NASDAQ: IMVT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.04 (+2.22% 1D, market cap $5.87B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IMVT ranks #526 in composite RQD confidence.

How does IMVT compare to KOD and CGON in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMVT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KOD (Kodiak Sciences Inc) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $6.14B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, IMVT leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMVT?

Per IMVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001764013), Immunovant Inc. generated $1.67B in revenue (+22.2% YoY), -$505.6M in net income, and -$407.3M in free cash flow against $1.05B in total assets and $29.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMVT trading relative to its 50-day, 200-day, and 52-week technical levels?

IMVT last traded at $29.04 (+2.22% on volume of 1,079,804 shares), positioning the stock -13.03% below its 50-day simple moving average ($33.39) and -9.53% below its 200-day simple moving average ($32.10). Across its 52-week range of $21.43 to $45.42, IMVT sits at the 31.7% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($26.95 to $31.13).

Direct Sub-Reports: IMVT RQD Cockpit IMVT 12M Forecast IMVT Earnings & Move IMVT Dividends & DRIP IMVT Insiders & 13F IMVT Whale Options IMVT Profit Sankey IMVT News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

IMVT — Immunovant Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Immunovant Inc. (IMVT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $29.04 (+2.22% 1D, market capitalization $5.87B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -36.0%, and free cash flow yield of -6.65%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 0.98x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Immunovant Inc. (IMVT) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the source data shows no revenue generation across the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Immunovant Inc. (IMVT) reported $1.67B in annual revenue (up from $1.37B in FY2024, +22.2% YoY) and -$505.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($856.8M revenue, -$259.3M net income) through FY2025, IMVT scaled operating cash flow to -$407.3M and free cash flow to -$407.3M, backed by $1.05B in total assets against $29.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.65% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $21.43 – $45.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -36.0% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is Health Care / Biotechnology: Biological Products, and beta is 0.98.

  • Key Question #1: Can IMVT sustain or expand its -36.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.67B and free cash flow of -$407.3M, how will capital allocation balance growth reinvestment against $29.8M in total debt?
  • Key Question #3: How sensitive is IMVT's 36.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

IMVT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immunovant Inc. (IMVT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMVT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMVT Bull vs. Bear Conversation Board — What's Your Call at $29.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMVT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IMVT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $35.59 (+22.0%)
📌 Pinned Debate

Forensic balance sheet is the strongest pillar, with Debt/Equity of 0.03 and cash of $994.5M in FY 2025 against debt of $29.8M.

Picked up a starter position in IMVT in my $100K Virtual Cash book at $29.17. Forensic balance sheet is the strongest pillar, with Debt/Equity of 0.03 and cash of $994.5M in FY 2025 against debt of $29.8M.. Trading inside a $21.43–$45.42 52-week range with -6.65% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — IMVT's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $22.75 (-22.0%)
Spot @ $29.17

The company reports $0.0M revenue with operating losses of -$596.6M and FCF of -$407.3M in FY 2025, and ROIC is -35%.

Careful chasing IMVT at $29.17. The company reports $0.0M revenue with operating losses of -$596.6M and FCF of -$407.3M in FY 2025, and ROIC is -35%.. Gross margin is 0.0%, but operating margin is -36.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $22.75 on multiple compression.

LIVE TAPE